BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
96.25
+0.25 (0.26%)
At close: Dec 5, 2025, 4:00 PM EST
97.09
+0.84 (0.87%)
After-hours: Dec 5, 2025, 7:17 PM EST
BioNTech SE Revenue
BioNTech SE had revenue of 1.52B EUR in the quarter ending September 30, 2025, with 22.02% growth. This brings the company's revenue in the last twelve months to 3.15B, up 3.70% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
3.15B EUR
Revenue Growth
+3.70%
P/S Ratio
6.24
Revenue / Employee
465,520 EUR
Employees
6,772
Market Cap
23.14B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BNTX News
- 2 days ago - BioNTech Achieves Minimum Condition in CureVac Exchange Offer - GlobeNewsWire
- 4 days ago - FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
- 4 days ago - Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men - Market Watch
- 9 days ago - BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration - GlobeNewsWire
- 18 days ago - BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript - Seeking Alpha
- 22 days ago - Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up - Reuters
- 22 days ago - Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run - Benzinga
- 22 days ago - BioNTech says collaboration with Pfizer remains unchanged - Reuters